S&P 500 Healthcare Sector SEC Filings — July 29, 2026

Q2 net sales grew 7.5% YoY (7.0% organic), beating guidance; adjusted EPS of $0.86 exceeded the $0.82–$0.84 range. Strong operating leverage with operating income up 44% YoY to $1.178B.

Q2 total revenues surged 26.2% YoY to $40.9B, with net income up 27.3% YoY to $694M. Insurance segment benefit ratio of 91.2% was in line with guidance, and individual Medicare Advantage membership is expected to grow ~25% over 2025.

Growth Portfolio revenue increased 24% YoY to $1.06B, partially offsetting a 13% decline in the Legacy MS portfolio. This product mix shift is a positive long-term signal despite near-term margin pain.

Operating cash flow improved significantly to $3.22B for H1 2026 from $1.60B a year ago, doubling and indicating strong cash generation.

Announced a $500M partial redemption of 4.25% Notes due 2027, reducing debt load and interest expense. This proactive deleveraging signals financial discipline and balance sheet strength.

Maintained operational sales growth guidance of 6.5%-7.1% despite lowering EPS guidance, indicating top-line momentum remains intact. Reported sales growth of 7.0%-7.6% confirms execution.

GAAP diluted EPS fell 85% YoY to $0.66, and Non-GAAP diluted EPS declined 34% to $3.60, driven by $165.4M in restructuring charges and $164.0M in acquired IPR&D from the Apellis acquisition. Earnings quality is severely impaired.

Adjusted EPS guidance for FY 2026 of 'at least $9.00' implies a ~47.5% decline from FY 2025 Adjusted EPS of $17.14. The GAAP EPS guidance was revised downward by ~22% to 'at least $6.52' from 'at least $8.36'.

Q3 2026 net sales guidance of only 3–5% growth represents a notable deceleration from Q2's 7.5% pace, suggesting headwinds in the near term.

Cash and cash equivalents plummeted to $1.285B from $3.009B at year-end 2025, a 57% decline, driven by the $5.065B Apellis acquisition. Financial flexibility is reduced.

EVP & Chief Mfg and Supply Chain Officer sold 84 shares total (~$30K) under a 10b5-1 plan. While small in value, the sale is a minor negative signal from an insider.

Net investment income declined 7.0% in Q2 and 3.9% for H1 2026, and the company reported an other comprehensive loss of $20M vs. income of $85M a year ago, reflecting unrealized investment losses.

GAAP net income plunged 84.6% to $97.5M in Q2 2026 from $634.8M, driven by a 36.9% surge in total costs and expenses to $2.6B. R&D expense rose 32.7% and SG&A rose 21.6%, both outpacing revenue growth of 3.4%.

GAAP EPS guidance was slashed by ~22% from 'at least $8.36' to 'at least $6.52', citing a Star Ratings headwind. The adjusted EPS guidance of 'at least $9.00' implies a 47.5% YoY decline from FY2025, signaling structural margin pressure.

Cash and equivalents fell 57% to $1.285B from $3.009B at year-end 2025, largely due to the $5.065B Apellis acquisition. The company's ability to fund operations or further M&A is constrained.

The Firefly Bio and Sail Biomedicines deals are expected to reduce 2026 adjusted EPS by ~$0.64 and 2027 adjusted EPS by ~$1.36. Full-year 2026 adjusted EPS guidance midpoint was lowered 5.9% to $11.04.

Q3 2026 net sales guidance of 3–5% growth is a sharp deceleration from Q2's 7.5% pace, suggesting potential market share loss or demand softening.

Net investment income fell 7.0% in Q2 and 3.9% for H1 2026, and other comprehensive loss of $20M in Q2 vs. income of $85M a year ago indicates portfolio stress.

The Legacy MS portfolio continued to decline 13% YoY, and VUMERITY revenue fell 7%, indicating ongoing erosion of the core business.

Short-term debt jumped to $2.3B at June 30, 2026 from $0 at year-end 2025, a significant increase in near-term liabilities that could pressure liquidity.

Urology segment growth was nearly flat at 1.1% reported (0.8% operational), suggesting competitive headwinds or market saturation.

EVP, GC and Secretary Quinn Michelle had 2,069 shares withheld for taxes at $86.88 (~$180K). While routine, it reduces insider holdings and could signal lack of conviction to add shares.

Q2 adjusted EPS of $0.86 beat guidance ($0.82–$0.84), and operating income surged 44% YoY. Despite Q3 guidance deceleration, the company's strong execution and beat-and-raise potential create a buying opportunity on any pullback.

Operating cash flow doubled to $3.22B in H1 2026 from $1.60B a year ago. With the stock likely oversold on guidance cuts, the strong cash generation provides a margin of safety for value investors.

The Growth Portfolio (up 24% YoY) now represents a larger share of revenue, reducing dependence on the declining MS franchise. As the Apellis integration matures, margin recovery could drive significant EPS upside.

The $500M debt redemption reduces interest expense and improves credit metrics. With ~$568.7M of the 4.25% Notes still outstanding, further redemptions could be a catalyst for credit upgrades and equity re-rating.

Individual Medicare Advantage membership is expected to grow ~25% over 2025, providing a strong volume driver. If the Star Ratings headwind is temporary, the stock could re-rate significantly.

Despite EPS dilution from M&A, J&J maintained operational sales growth guidance of 6.5%-7.1% and reported 7.0%-7.6% growth. The Firefly Bio and Sail Biomedicines deals could unlock long-term value in oncology and RNA therapeutics.

The election of Paul Smith (Anthropic CCO) and Frederick Crawford (former Aflac President/COO) brings AI/tech expertise and deep insurance financial experience. This governance upgrade could drive operational improvements and strategic pivots.

Total assets increased to $57.2B from $48.9B at year-end 2025, and total equity rose to $19.3B from $17.7B, providing a strong balance sheet to support the turnaround despite cash burn.

With strong Q2 results and a robust pipeline, any positive readouts or FDA approvals in the coming quarters could reverse the Q3 guidance deceleration narrative.

Redeeming 4.25% notes in a potentially lower rate environment reduces refinancing risk. If rates decline further, the remaining $568.7M could be refinanced at lower costs, boosting net interest margin.

3 of 4 major companies (Biogen, Humana, J&J) reported top-line growth but experienced significant EPS headwinds from M&A costs, restructuring, or guidance cuts. This theme suggests that sector earnings quality is deteriorating despite revenue momentum.

Biogen's cash and equivalents fell 57% after the $5.065B Apellis acquisition, and J&J's EPS guidance was cut by $0.64 due to Firefly Bio and Sail Biomedicines deals. The sector is prioritizing strategic acquisitions over near-term profitability, reducing financial flexibility.

Only 2 insider transactions were reported (Medtronic tax withholding, Intuitive Surgical small 10b5-1 sale), both neutral to slightly negative. The lack of insider buying across the sector suggests management teams are not aggressively signaling confidence in current valuations.

Humana's adjusted EPS guidance implies a 47.5% YoY decline, driven by Star Ratings headwinds and rising medical costs. This signals that managed care companies face structural margin compression despite strong membership growth.

Centene is deleveraging ($500M debt redemption), while Biogen and J&J are spending heavily on M&A. This divergence creates a barbell: cash-rich, disciplined companies vs. growth-through-acquisition stories with near-term earnings dilution.

Biogen's Growth Portfolio (up 24% YoY) is offsetting a 13% decline in the Legacy MS portfolio. This product mix shift is a sector-wide theme as companies pivot from mature franchises to higher-growth areas, but it comes with transition costs.

Monitor Q3 2026 earnings for signs of margin recovery as Apellis integration progresses. Cash burn rate and any further restructuring charges are key. Next earnings call expected late October 2026.

Watch for Star Ratings updates and any further guidance revisions. The Q3 2026 earnings call (expected late October) will be critical to assess if the 'at least $9.00' adjusted EPS guidance is achievable.

Q3 2026 results (expected late October) will confirm if the 3–5% growth guidance is conservative or a sign of demand softening. Urology segment performance is a key metric to watch.

Monitor for updates on Firefly Bio and Sail Biomedicines milestones, which could trigger additional EPS charges in 2027. The next earnings call will provide clarity on integration progress.

The August 13, 2026 redemption date for the $500M notes is a near-term event. Watch for any further debt reduction announcements or credit rating actions.

Monitor insider trading patterns. The small 10b5-1 sale by the EVP of Manufacturing is minor, but any acceleration of insider sales would be a red flag.

Paul Smith (Anthropic) and Frederick Crawford (Aflac) joined the board. Watch for any strategic shifts or AI-driven operational improvements announced in the coming quarters.

With 3 of 4 major companies reporting margin compression, the Q3 2026 earnings season will be crucial to see if this is a temporary phenomenon or a structural shift.